UH lands $1.2M NIH grant to fight superbugs using AI, quantum sensing

drug defense

UH chemistry professors Yuhong Wang and Shoujun Xu are using new technology and approaches to fight drug-resistant superbugs. Photo courtesy UH

The fight against antibiotic-resistant bacteria like MRSA is getting science fiction-like upgrades at the University of Houston thanks to a new four-year, $1.26 million grant from the National Institutes of Health.

The university says the recent funding brings total federal support up to $3.5 million for 11 years for the project, which uses AI and quantum-sensing technology to better understand how bacterial proteins develop resistance to drugs.

Any medical professional will tell you that one of the worst things that can happen is almost killing an infection. Bacteria that survive attacks from conventional antibiotic treatments emerge tougher, more resistant and more aggressive than before–making them much harder to treat. A good example is the superbug methicillin-resistant Staphylococcus aureus (MRSA).

UH chemistry professors Yuhong Wang and Shoujun Xu are working on this issue. They know full well that fighting superbugs requires new technology and new approaches, which is what they aim to pioneer with their new grant.

“Drug-resistant bacterial infections such as MRSA are becoming harder to treat, creating an urgent need for faster ways to understand how antibiotics and other small molecules interact with bacterial proteins,” Wang said in a news release.

Wang and Xu’s work centers around GTP, a cellular fuel that can cause tiny changes to a cell's structure when it mutates. Sometimes, those shape changes make it easier for drugs to breach the wall and attack the cells.

The UH scientists are employing AlphaFold, an AI-powered tool that can scan large molecular libraries in seconds. From these models, they can see promising drug combinations for future testing.

Once identified, the team uses their invention, super-resolution force spectroscopy, to monitor the cells. Tiny magnetic beads are attached to genetic material, then magnified to see how strong that material is when pulled. They can measure this incredible microscopic process through an atomic magnetometer, typically used in quantum physics. Combined, all these tools allow a high-definition look at how each molecule might respond to new chemical approaches.

“We're the only chemists in the world that use an atomic magnetometer for biological research,” Xu said. “It's a technique developed by physicists, and there is usually a gap between techniques developed by physicists and biological applications. Yuhong and I have been bridging that gap together for the past 10 years.”

Eventually, Wang and Xu hope to develop powerful software that can be used by drug manufacturers to model cellular responses. With enough predictive data, the software could even get ahead of superbugs’ own mutation, allowing drugs to be developed before new strains arrive.

"We want an algorithm where you input a protein sequence, score the mutation hotspots, and develop new inhibitors before a drug-resistant species even emerges," Wang added.

From Your Site Articles
Houston Methodist researchers have developed an implantable device that could help bypass spinal injuries. Photo via Getty Images

Houston researchers develop breakthrough device that could bypass spinal injuries

breakthrough research

Scientists at Houston Methodist have announced a significant leap forward for spinal cord injury recovery.

The researchers have developed a device that essentially bypasses spinal injuries, allowing signals from previously “lost” functions to reach the brain, a new study published in Nature Communications shows.

“Most current technologies try to improve whatever function remains after a spinal cord injury,” Dr. Damiano Barone, assistant professor of neurosurgery in the Department of Neurosurgery at Houston Methodist and co-lead on the study, said in a news release. “Our goal is different. Rather than fixing the injury itself, we want to bypass it completely and create an alternative route for signals to travel.”

The study involved a single ultrathin circumferential electrode array made to conform around the spinal cord without penetrating neural tissue, which was implanted into rodent and pig models with spinal injuries. The electrode array was able to interpret motor, sensory and autonomic signals around the injury. Think of it as a set of detours that restore road access to isolated towns after a disaster destroys the highway instead of just rebuilding the highway.

Over the course of three days, the arrays detected signals of intended movement from low-frequency spinal oscillations with more than 94 percent accuracy. This worked across species and was replicated in feasibility studies on human cadavers.

This research could serve as a new foundation for neuroprosthetic implants that could restore connectivity to the 2.5 million people worldwide suffering from spinal injuries that result in loss of ability. Future development could result in everything from restored organ function to mobility, according to Houston Methodist.

George Malliaras, the Prince Professor of Technology in the Department of Engineering at the University of Cambridge, who co-led the study, sees it as a fundamental restructuring of the science of spinal trauma.

“This could represent a paradigm change in how we think about spinal cord injuries,” Malliaras said. “Instead of starting from the idea that what is lost is gone forever, this approach asks whether we can restore function by carrying the signal around the injury.”

Further work involving laboratory models will need to be completed before launching human trials.

Grants from the National Institutes of Health, Houston Methodist Katz Investigator Award, Helaers Research Award and the Engineering and Physical Sciences Research Council helped support the study. Other collaborators on the study include Salim Hadwe, Ruben Serrano, George Psaltakis, Margaux Forner, Chaeyeon Lee, Sydney Swedick, Moleca Ghnnam, Tawfique Hasan and Alejandro Carnicer-Lombarte from the University of Cambridge; and Anton Banta and Xueer Zhang from Houston Methodist.

The 10-year study will investigate why the immune system attacks healthy tissue in people with autoimmune diseases. Photo via Pexels

UH lands $4M NIH grant to study early signs of autoimmune disease

NIH funding

The University of Houston recently received a $4 million National Institutes of Health grant to support a 10-year longitudinal study to identify the earliest biological markers of autoimmune disease.

Led by Chandra Mohan, the Hugh Roy and Lillie Cranz Cullen Endowed Professor of Biomedical Engineering, the study aims to examine what causes Systemic Autoimmune Rheumatic Diseases (SARDs) and to identify targets for future treatments. The study will be carried out in collaboration with Dr. Karen Costenbader at Harvard Medical School, Boston.

SARDs include conditions like rheumatoid arthritis, systemic lupus erythematosus, Sjögren’s syndrome and systemic sclerosis—all are considered chronic diseases currently without a cure. Autoimmune diseases affect over 30 million people globally, according to UH.

SARDs occur when the body’s immune system attacks healthy, non-threatening tissues and organs. According to UH, in these diseases, the body often attacks nuclear antigens, creating anti-nuclear autoantibodies, which can be early detection signs for SARDs in more than 50 percent of patients, Mohan says.

Researchers will study blood samples and environmental exposure over the 10 years to better understand anti-nuclear autoantibodies.

“Collectively, these studies will help identify the genetic, environmental and cellular factors that are operative at the two steps of SARD development, namely the emergence of anti-nuclear autoantibodies and disease onset,” Mohan said in a news release. “ More importantly, these studies will highlight functional molecular pathways and mechanisms that may be operative at each step."

Mohan predicts that looking at SARDs’ shared characteristics, rather than each disease individually, could help identify more treatment methods.

“Individual SARDs have been examined in silos without an attempt to discern shared underlying features at the molecular level,” he added in the release. “Current understanding of the initial (and likely shared) origins of SARDs is only rudimentary but urgently needed to develop means for prevention and treatment.”

Earlier this year, UH also received an $11 million NIH grant to conduct a first-of-its-kind study of early language development in children ages 18 to 24 months. Read more here.

CellChorus has landed its latest SBIR award. Photo via Getty Images

Houston health tech co. lands NIH grant for AI cancer prediction tool

fresh funding

Houston-based CellChorus and Stanford Medicine were recently awarded a Phase I Small Business Innovation Research grant for the company's AI platform to test how certain cancer patients will respond to therapies.

The funding comes from the National Cancer Institute of the National Institutes of Health. According to a filing, the grant totaled just under $400,000.

CellChorus, which spun out from the University of Houston’s Technology Bridge, has developed TIMING (Time-lapse Imaging Microscopy In Nanowell Grids), which analyzes the behavior of thousands of individual immune cells over time and can identify early indicators of treatment success or failure.

The company will work with Stanford's Dr. David Miklos and Dr. Saurabh Dahiya, who have built the Bone Marrow Transplantation and Cell Therapy Biobank. The biobank manages and stores biological samples from patients treated at their clinic and in clinical trials.

"Predicting which patients will achieve durable responses after CAR-T therapy remains one of the most important challenges in the field,” Miklos said in a news release. “We aim to uncover functional cellular signatures that can guide treatment decisions and improve patient outcomes.”

The project will specifically profile cells from patients with relapsed/refractory large B-cell lymphoma (r/rLBCL). According to CellChorus, only about half of r/rLBCL patients who receive CAR-T therapy "achieve a durable, long-term remission." Others do not respond to therapy or experience relapse.

“The sooner we know whether a cancer therapy is working, the better. To maximize patient benefit, we need technology that can provide a robust and early prediction of response to therapy. The technology needs to be scalable, cost-efficient, and capable of rapid turnaround times,” Rebecca Berdeaux, chief scientific officer of CellChorus, added in the release. “We are excited to work with Drs. David Miklos and Saurabh Dahiya and their colleagues on this very important project.”

CellChorus has previously received SBIR grants from federal agencies, including a $2.5 million award in 2024 from its National Center for Advancing Translational Sciences (NCATS) and a $2.3 million SBIR Fast-Track award from the National Institute of General Medical Sciences in 2023.

Dr. Hina Faisal will test the effects of VR games on patients coming out the ICU, thanks to a recent NIH grant. Photo via Getty Images.

Houston doctor wins NIH grant to test virtual reality for ICU delirium

Virtual healing

Think of it like a reverse version of The Matrix. A person wakes up in a hospital bed and gets plugged into a virtual reality game world in order to heal.

While it may sound far-fetched, Dr. Hina Faisal, a Houston Methodist critical care specialist in the Department of Surgery, was recently awarded a $242,000 grant from the National Institute of Health to test the effects of VR games on patients coming out of major surgery in the intensive care unit (ICU).

The five-year study will focus on older patients using mental stimulation techniques to reduce incidences of delirium. The award comes courtesy of the National Institute on Aging K76 Paul B. Beeson Emerging Leaders Career Development Award in Aging.

“As the population of older adults continues to grow, the need for effective, scalable interventions to prevent postoperative complications like delirium is more important than ever,” Faisal said in a news release.

ICU delirium is a serious condition that can lead to major complications and even death. Roughly 87 percent of patients who undergo major surgery involving intubation will experience some form of delirium coming out of anesthesia. Causes can range from infection to drug reactions. While many cases are mild, prolonged ICU delirium may prevent a patient from following medical advice or even cause them to hurt themselves.

Using VR games to treat delirium is a rapidly emerging and exciting branch of medicine. Studies show that VR games can help promote mental activity, memory and cognitive function. However, the full benefits are currently unknown as studies have been hampered by small patient populations.

Faisal believes that half of all ICU delirium cases are preventable through VR treatment. Currently, a general lack of knowledge and resources has been holding back the advancement of the treatment.

Hopefully, the work of Faisal in one of the busiest medical cities in the world can alleviate that problem as she spends the next half-decade plugging patients into games to aid in their healing.

BCM's Center for Precision Medicine Models has received funding that will allow it to study more complex diseases. Photo via Getty Images

Baylor center receives $10M NIH grant to continue rare disease research

NIH funding

Baylor College of Medicine’s Center for Precision Medicine Models received a $10 million, five-year grant from the National Institutes of Health last month that will allow it to continue its work studying rare genetic diseases.

The Center for Precision Medicine Models creates customized cell, fly and mouse models that mimic specific genetic variations found in patients, helping scientists to better understand how genetic changes cause disease and explore potential treatments.

The center was originally funded by an NIH grant, and its models have contributed to the discovery of several new rare disease genes and new symptoms caused by known disease genes. It hosts an online portal that allows physicians, families and advocacy groups to nominate genetic variants or rare diseases that need further investigation or new treatments.

Since its founding in 2020, it has received 156 disease/variant nominations, accepted 63 for modeling and produced more than 200 precision models, according to Baylor.

The center plans to use the latest round of funding to bring together more experts in rare disease research, animal modeling and bioinformatics, and to expand its focus and model more complex diseases.

Dr. Jason Heaney, associate professor in the Department of Molecular and Human Genetics at BCM, serves as the lead principal investigator of the center.

“The Department of Molecular and Human Genetics is uniquely equipped to bring together the diverse expertise needed to connect clinical human genetics, animal research and advanced bioinformatics tools,” Heaney added in the release. “This integration allows us to drive personalized medicine forward using precision animal models and to turn those discoveries into better care for patients.”

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Property Showcase

UTMB launches new department for space medicine, names inaugural leader

department launch

In space, no one can hear you scream—but they can hear you discuss your medical history and recent symptoms.

The University of Texas Medical Branch (UTMB) announced last month that it would form a new Department of Aerospace and Exploration Medicine within its School of Public and Population Health under the leadership of Dr. Ronak V. Shah, who will serve as inaugural chair.

“Human exploration is changing rapidly, and the health challenges associated with distance, isolation, and limited resources are changing along with it,” Shah said in a news release. “Creating the Department of Aerospace and Exploration Medicine gives us an opportunity to build on decades of expertise at UTMB as we prepare for the future.”

The new department elevates UTMB’s existing Aerospace Medicine Division and provides "broader academic structure for expanding research, education, and collaboration across disciplines," according to the release. Shah was previously named director of the division in 2022 after serving as medical director of Johnson Space Center.

Space exploration in particular has a wide variety of highly specific medical side effects that are in need of the formalized study that the department will specialize in. For example, zero- and low-gravity environments cause everything from detached fingernails to flattened eyeballs. Even in modern, high-tech spacecraft, the human body feels the impacts of space.

It’s an area of medicine UTMB is uniquely suited for. Starting in the 1950s with NASA’s director of medical research Dr. Charles A. Berry, UTMB partnered with the blossoming era of exploration by monitoring astronauts. In 1993, UTMB and the NASA Johnson Space Center created the joint Aerospace Medicine Residency Program, which used bed facilities at the Galveston branch to simulate weightlessness. Wherever there has been a question about how flight and space affect health, odds are UTMB has been involved.

The Department of Aerospace and Exploration Medicine will launch several new initiatives soon. One planned for 2027 is an Undersea and Hyperbaric Medicine Fellowship that will allow scientists to study the physiology of high-pressure flight.

“In the era of a growing global space economy, we are revisiting questions such as who is flying, what is their destination, what vehicle will get them there?” Shah added in the release. “The answers to these questions will drive what research is needed and how we train the next generation.”

Energy AI company opens first U.S. office at Houston’s the Ion

Building on its partnership with Houston-based oilfield services provider Halliburton, energy-sector AI company Shape Digital recently opened an office at The Ion. It’s the company’s first U.S. location.

Shape Digital’s workforce in Houston includes employees specializing in tech support, business development and client services. The company’s local hiring projections and headcount weren’t available. The new office will be located within Industrious at the Ion, according to Rice Alliance.

A key driver of the new Houston office: The company forecasts North America will account for more than 20 percent of its business in 2027.

“North America is a critical market for industrial innovation, and Houston sits at the center of companies driving that progress,” Caio Sene, vice president of client services at Shape Digital, said in a release. “Growing our presence here allows us to work alongside operators as they look for practical ways to turn existing operational data into clear recommendations for what to do next.”

Shape Digital, which also has offices in Singapore and Brazil, develops decision-making platforms for the oil and gas sector.

The Ion District office gives Shape Digital a presence close to Halliburton’s headquarters. In May, the two companies forged a partnership to combine Halliburton’s Digital Field Solverdecision-making system with Shape Digital’s AI portfolio.

Shape Digital layers AI software atop existing operations data rather than replacing legacy systems or adding new software.

The company’s suite of AI agents draws on more than 200 operations-monitoring algorithms, continually learning from company and industry data. The suite comprises four products: Shape Aura, Shape Lighthouse, Shape Lumen and Shape Reef.

Shape Digital says that by working with a customer’s existing operations data, it can deliver ROI in less than two months without any additional investment in equipment or infrastructure.

The company is a 2021 spinoff of Japan-based Modec. Modec builds, owns, and operates floating offshore oil and gas production facilities. Its Modec America subsidiary is based in Houston.

Meet the esteemed judges for the 2026 Houston Innovation Awards

Meet The Judges

Editor's note: Judging is now underway for the 2026 Houston Innovation Awards, and it's time to meet the decision makers.

Our 2026 judging panel comprises past award winners who represent a variety of industries and areas of expertise. They are joined by InnovationMap's interim editor. All are deeply engaged in the Houston innovation ecosystem.

Our judging panel will review all nominee applications submitted across 10 prestigious categories. They will determine the 2026 finalists in all categories, and they will select the winners in all but one category — our people's choice award for Startup of the Year.

The sixth annual Houston Innovation Awards program will be presented in an all-digital format in 2026. We will announce this year's finalists and feature their stories throughout our special editorial series this fall. Then, stay tuned as we reveal the 2026 Houston Innovation Awards winners on InnovationMap.com in mid-November.

Sagar Dalal, Fervo Energy, 2025 Scaleup of the Year

Sagar Dalal

Sagar Dalal serves as chief of staff at Fervo Energy, a company pioneering the commercialization of next-generation geothermal power. In this role, he helps translate the CEO’s vision and priorities into execution, leading cross-functional strategic initiatives that support the company’s growth and operations.

Dalal brings nearly eight years of experience in structural engineering and project management from his time at Thornton Tomasetti and Tesla, where he engineered and built a wide range of infrastructure projects ranging from stadiums to manufacturing facilities. He holds an MBA from Stanford University and an MS in Civil Engineering from Texas A&M University. He is also a licensed professional engineer.

Aaron Fitzgerald, Mars Materials, 2025 Minority-founded Business of the Year

Aaron Fitzgerald

Aaron Fitzgerald is a three-time founder and carbon removal entrepreneur focused on reimagining how we make things. As the CEO of Mars Materials, he leads a team working to commercialize technologies that sequester captured carbon into industrial supply chains.

His vision for a defossilized future is shaped by a unique path through both policy, including a tenure in the United States Senate, and deep carbontech, with fellowships at The Lewis Latimer program, Breakthrough Energy, Prime Coalition, and Carbon 180.

Tatiana Fofanova, Koda Health, 2025 Health Tech Business of the Year

Tatiana Fofonova

Tatiana Fofanova, PhD, is the co-founder and CEO of Koda Health, an AI-enhanced patient decision support platform designed to make advance care planning (ACP) scalable, accessible, and patient-centered for patients with serious illness.

After earning her PhD in Translational Medicine at Baylor College of Medicine, she joined Texas Medical Center (TMC) as a Founder-in-Residence. It was there that she and her co-founders identified one of the most overlooked yet critical gaps in healthcare: the lack of meaningful, accessible advance care planning. Under her leadership, Koda Health now supports over 1 million patients through partnerships with organizations like Cigna, Privia, and Houston Methodist.

Lawson Gow, Greentown Labs, 2025 Incubator/Accelerator of the Year

Lawson Gow currently serves as chief strategy officer for Greentown Labs, which was named Incubator/Accelerator of the Year in the 2025 Houston Innovation Awards. Prior to joining Greentown Labs as Head of Houston in 2025, Gow was as a managing partner at Helium Capital, an investment and advisory firm that aims to support founders across the entire lifecycle of entrepreneurship.

He is also the founder of The Cannon, an innovation-infrastructure provider that operates a growing network of innovation hubs for its community of startups, entrepreneurs, investors, and corporate innovators.

Sarah Hein, March Biosciences, 2025 Female-founded Business of the Year

Sarah Hein

Sarah Hein is the founding CEO of March Biosciences, a clinical-stage cell-therapy company targeting challenging malignancies. Prior to cofounding March Biosciences, she was the founding Entrepreneur in Residence for the Texas Medical Center Innovation Accelerator for Cancer Therapeutics (TMCi ACT).

Formerly, she was a cofounder and the vice president of operations at Courier Therapeutics, a cancer immunotherapy startup acquired by Valo Health. She was also director of research at Resonant Therapeutics, an antibody therapeutics platform technology company. She began at Mercury Fund as a Venture Fellow directly after graduating with her PhD in Molecular Biology from Baylor College of Medicine.

Tanu Jain, FlowCare, 2025 Startup of the Year

Tanu Jain

Tanu Jain is a product executive, entrepreneur, founder and CEO of FlowCare, and registered nurse with a track record of building products from zero to global scale. She previously led product at BioIQ before founding FlowCare, a Houston-based period care infrastructure platform making period care a standard in every restroom. In under 16 months, FlowCare has signed deployed across four enterprise customers and impacted more than 1.5 million women.

FlowCare was named Startup of the Year at the 2025 Houston Innovation Awards, and Jain has been recognized with additional honors including the SDG Super Changemaker – Pewter — at the Global Sustainability Awards 2026.

Prabhdeep "Prab" Sekhon, Eclipse Energy, 2025 Energy Transition Business of the Year

Prabhdeep Singh Sekhon

Prabhdeep Singh Sekhon is CEO of Eclipse Energy, an energy technology company transforming depleted oil fields into low-cost, sustainable hydrogen resources through subsurface biotechnology. He brings nearly two decades of global energy experience spanning climate technology, venture capital, private equity, and multi-billion-dollar energy projects across five continents.

Previously, he held leadership roles at NextEra Energy Resources and Hess Corporation. He is also a founder and managing director of GreenLite Resources and a founding member of Cotogna Sports Group. He holds an MBA from Wharton, a Masters in Engineering from Texas A&M, and a BS from the University of Calgary.

Wade Pinder, Product Houston, 2025 Trailblazer Award Winner

Wade Pinder thinks of himself as an "ecosystem wayseeker," helping founders and builders in and around Houston find their footing, understand the landscape, and move through uncertainty with more clarity. Through Product Houston, he works at the intersection of product strategy, founder support, ecosystem mapping, and community-building, with a particular focus on helping people show up in the right rooms before they feel fully ready.

His background includes years in product management at Blinds.com and Home Depot, along with founding and leading the Houston Product Community for six years. He was recognized by as Mentor of the Year in the 2023 Houston Innovation Awards and received the Trailblazer Award in 2025.

Laura Furr Mericas, Interim Editor, InnovationMap

Laura Furr Mericas is interim editor for InnovatonMap.com and EnergyCapitalHTX.com. She is a longtime contributor to both sites and has reported on Houston's innovation ecosystem for InnovationMap since 2020. Previously, she served as web editor and data reporter for Houston Business Journal.

View All Listings